文献速递泌尿男性生殖肿瘤

NeuroSAFE引导的机器人辅助根治性前列腺切除术与标准机器人辅助根治性前列腺切除术对局限性前列腺癌患者勃起功能和尿控的影响(NeuroSAFE PROOF):一项多中心、患者盲法、随机对照3期试验

Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-03-24

NeuroSAFE PROOF是一项在5家英国国家医疗服务体系医院开展的多中心、患者盲法、随机对照3期试验,纳入407例局限性前列腺癌患者,381例接受手术并纳入改良意向性治疗分析。结果显示,NeuroSAFE引导的RARP组12个月时IIEF-5评分平均为12.7(SD 8.0),标准RARP组为9.7(7.5),调整后平均差3.18(95%CI 1.62至4.75;p<0.0001);3个月时ICIQ评分显著低于标准组,6个月时无显著差异。结论认为NeuroSAFE引导神经保留可改善患者报告的12个月IIEF-5评分和短期尿控。

要点

  • NeuroSAFE引导RARP组12个月IIEF-5评分平均12.7,标准RARP组9.7,调整后平均差3.18(95%CI 1.62-4.75;p<0.0001)。
  • 3个月ICIQ评分NeuroSAFE组显著低于标准组(调整后平均差-1.41,95%CI -2.42至-0.41;p=0.006),6个月无显著差异。
  • 严重不良事件NeuroSAFE组6/190(3%),标准组5/191(3%),均为术后并发症,无归因于研究干预的严重不良事件或死亡。

核心结论

  • 在RARP中利用NeuroSAFE引导神经保留可改善患者报告的12个月IIEF-5评分和短期尿控。
  • 对于按标准实践不会接受双侧神经保留的患者,勃起功能获益更明显。

研究设计与样本

  • NeuroSAFE PROOF为多中心、患者盲法、随机对照3期试验,在英国5家国家医疗服务体系医院开展。
  • 2019年1月6日至2022年12月6日共招募407例患者,381例接受手术并纳入改良意向性治疗分析(NeuroSAFE组190例,标准RARP组191例)。
  • 主要结局为12个月时IIEF-5评分,344例有主要结局数据(NeuroSAFE组173例,标准RARP组171例)。
  • 中位随访12.3个月(IQR 11.8-12.7)。

主要发现

  • 12个月时平均IIEF-5评分NeuroSAFE组12.7(SD 8.0)vs 标准RARP组9.7(7.5),调整后平均差3.18(95%CI 1.62至4.75;p<0.0001)。
  • 3个月时ICIQ评分NeuroSAFE组显著低于标准RARP组,调整后平均差-1.41(95%CI -2.42至-0.41;p=0.006)。
  • 6个月时ICIQ评分两组无显著差异,调整后平均差-0.37(95%CI -1.35至0.62;p=0.46)。
  • 12个月时平均IIEF-6评分NeuroSAFE组15.3(SD 9.7)vs 标准RARP组11.5(SD 9.0),调整后平均差3.92(95%CI 2.01至5.83;p<0.0001)。
  • 严重不良事件NeuroSAFE组6/190(3%)vs 标准RARP组5/191(3%),均为术后并发症,无归因于研究干预的严重不良事件或死亡。

关键数值与推荐

  • 关键 eligibility 标准:非转移性前列腺癌适合行RARP,勃起功能良好(IIEF前5项评分≥22)且无需药物辅助,既往未接受前列腺癌治疗,无年龄限制。
  • 随机分组1:1,采用区组随机化,按中心分层。
  • 主要结局为改良意向性治疗人群12个月时IIEF-5评分;次要结局包括3个月和6个月ICIQ评分及12个月IIEF-6评分。

临床怎么用

  • 原文结论认为,在RARP中使用NeuroSAFE引导神经保留可改善患者报告的12个月IIEF-5评分和短期尿控。
  • 原文结论指出,对于按标准实践不会接受双侧神经保留的患者,勃起功能获益更明显。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sparing the periprostatic neurovascular bundles during robot-assisted radical prostatectomy (RARP) improves postoperative erectile function and early urinary continence recovery. The NeuroSAFE technique, a standardised frozen section analysis, enables accurate real-time detection of positive surgical margins during nerve-sparing, increasing the likelihood of successful nerve preservation. However, the impact of the technique on patient outcomes remains uncertain. We aimed to assess the effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence. METHODS: NeuroSAFE PROOF was a multicentre, patient-blinded, randomised, controlled phase 3 trial done at five National Health Service hospitals in the UK. Key eligibility criteria were a diagnosis of non-metastatic prostate cancer deemed suitable to undergo RARP, good erectile function (defined as a score of ≥22 on the first 5 items of the International Index of Erectile Function [IIEF]) without medical erectile function assistance, and no previous prostate cancer treatment. No age limits were applied. Participants were randomly assigned (1:1) to standard RARP or NeuroSAFE-guided RARP using block randomisation, stratified by site. Masking of participants to allocation was maintained throughout, but patients were informed of their nerve-sparing status after the operation. Due to the nature of the intervention, operating teams were aware of treatment group. Nerve-sparing was guided by a preoperative plan in the standard RARP group and by intraoperative NeuroSAFE assessment in the NeuroSAFE group. The primary outcome was erectile function at 12 months, assessed using the IIEF-5 score, in the modified intention-to-treat population, which included all randomly assigned participants who had surgery. Secondary endpoints were urinary continence scores at 3 and 6 months, evaluated using the International Consultation on Incontinence Questionnaire (ICIQ), and the erectile function domain of the IIEF (IIEF-6) scores at 12 months. The trial is registered at ClinicalTrials.gov, NCT03317990. FINDINGS: Between Jan 6, 2019, and Dec 6, 2022, 407 patients were recruited, of whom 381 had surgery (190 participants in the NeuroSAFE group and 191 participants in the standard RARP group), and were included in the modified intention-to-treat population. Data for the primary outcome (IIEF-5 score at 12 months) were available for 344 participants (173 in the NeuroSAFE group and 171 participants in the standard RARP group). Median follow-up was 12·3 months (IQR 11·8-12·7). At 12 months, the mean IIEF-5 score was 12·7 (SD 8·0) in the NeuroSAFE group versus 9·7 (7·5) in the standard RARP group (adjusted mean difference 3·18 [95% CI 1·62 to 4·75]; p<0·0001). At 3 months, the ICIQ score was significantly lower in the NeuroSAFE group than the standard RARP group (adjusted mean difference -1·41 [95% CI -2·42 to -0·41]; p=0·006). At 6 months, no significant difference in ICIQ score was observed between groups (adjusted mean difference -0·37 [95% CI -1·35 to 0·62]; p=0·46). At 12 months, the mean IIEF-6 score was higher in the NeuroSAFE group than in the standard RARP group (15·3 [SD 9·7] vs 11·5 [SD 9·0]; adjusted mean difference 3·92 [95% CI 2·01 to 5·83]; p<0·0001). Serious adverse events occurred in six (3%) of 190 patients in the NeuroSAFE group, and and in five (3%) of 191 patients in the standard RARP group. All adverse events were postoperative complications; no serious adverse events or deaths were attributed to the study intervention. INTERPRETATION: The use of NeuroSAFE to guide nerve-sparing during RARP improves patient-reported IIEF-5 scores at 12 months and short-term urinary continence. The erectile function benefit is enhanced in patients who would not otherwise have undergone bilateral nerve-sparing by standard practice. FUNDING: National Institute of Healthcare Research, JP Moulton Charitable Foundation, UCLH Charity, St Peters Trust, and Rosetrees Trust.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Dinneen E, Almeida-Magana R, Al-Hammouri T, et al. Effect of NeuroSAFE-guided RARP versus standard RARP on erectile function and urinary continence in patients with localised prostate cancer (NeuroSAFE PROOF): a multicentre, patient-blinded, randomised, controlled phase 3 trial. Lancet Oncol. 2025. PMID: 40147459. doi:10.1016/S1470-2045(25)00091-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。